“Building on the encouraging clinical findings in patients with solid tumors, together with robust preclinical data, we are eager to evaluate nadunolimab as a preventive treatment in this high‑risk population. We are excited that a leading institution such as the Tisch Cancer Institute recognizes nadunolimab as an innovative and promising therapeutic approach, and we look forward to advancing this treatment option further” said Hilde Steineger, CEO of Cantargia.

“Lung cancer is a leading cancer killer and while treatment options have improved, most lives are saved by early detection” said Dr. Robert Samstein, Mount Sinai Tisch Cancer Center. “The scientific rationale for using a novel IL1RAP-targeting approach with nadunolimab is compelling in this identified high-risk population, and we look forward to starting the study”.

Nadunolimab has been investigated by Cantargia in approximately 300 patients with solid tumor indications and has shown signals of clinical activity in pancreatic cancer and non-small cell lung carcinoma. Researchers at the Tisch Cancer Institute have a long-standing interest in developing new therapies for the treatment of lung cancer and have performed preclinical work strongly implicating IL-1 signaling in tumor initiation and the development of early lung cancer.

The new phase 2 investigator-initiated trial will be conducted at Mount Sinai Tisch Cancer Center, New York. The study, led by principal investigator Dr. Robert Samstein, is designed to investigate nadunolimab monotherapy in the high-risk population for 3 months. The study participants will then be screened repeatedly for 12 months, measuring the response of the lung nodules to treatment. In addition to investigating anticancer effects, the study will include comprehensive correlative studies to understand the effect IL1RAP targeting on inflammation contributing to cancer and other diseases. Details about the study (NCT07284485) are available at clinicaltrials.gov.